Dr. Warren P. Mason is the medical director of The Gerry & Nancy Pencer Brain Tumor Centre and the holder of the Kirchmann Family Chair in Neuro-Oncology Research. He graduated in medicine from the University of Toronto and completed residencies in internal medicine and neurology at the University of Toronto and McGill University. He is the chair of the CCTG Brain Disease Site Committee with the mandate of actively developing an investigational new drug program for glioma. His research interests are the medical treatment of brain tumors, particularly glioma, with an emphasis on novel drug evaluation for glioblastoma. The focus of Dr. Mason's current research is the development of medical therapies for primary brain tumors.
Dr. David Mathieu is a full professor at the Université de Sherbrooke within the Departments of Surgery, Division of Neurosurgery, and Nuclear Medicine and Radiobiology, in addition to holding the post of the director of the Neurosurgery Division and of the Gamma Knife Radiosurgery Center at the Centre Hospitalier Universitaire de Sherbrooke (CHUS). He serves on the board of directors of the International Radiosurgery Research Foundation (IRRF), a research organization dedicated to the development of multicentric stereotactic radiosurgery trials. Dr Mathieu is in charge of clinical research in neuro-oncology at CHUS and has completed numerous research collaborations with members of the Neuroscience Center and the Radiotherapy Research Center of the Université de Sherbrooke. His areas of expertise include neuro-oncology and stereotactic and functional neurosurgery.
Dr. James R. Perry is a professor of medicine (neurology) at the University of Toronto. He trained in neurology in Toronto, as well as clinical epidemiology, and completed a Neuro-Oncology Fellowship at Duke University. He had been a neuro-oncologist at the Sunnybrook Odette Cancer Centre since 1996. He has served as a provincial lead for CNS Cancers in Ontario, and he serves on a wide variety of editorial boards, advisory boards, and guidelines committees. He has led and participated in many practice-changing clinical trials, including the RESCUE study of daily metronomic temozolomide, the CCTG study of elderly GBM, and the INDIGO trial of vorasidenib.
Dr. David Roberge is a full professor at the University of Montreal and an adjunct professor at McGill University. He is a graduate of the McGill residency program in radiation oncology, and he completed post-residency fellowships at Stanford University and St. Jude Children’s Research Hospital. Currently, he is a clinician–researcher at CHUM (Centre hospitalier de l’Université de Montréal) in Montreal. His research interests are clinical research related to the treatment of cancers: radiosurgery, cutaneous hematology, neuro-oncology, pediatrics—young adults, and radio-oncology imaging. His research also includes post-operative treatments for brain metastasis, the conservative management of brain arteriovenous malformations, and the use of palliative radiotherapy for hepatic cancer.
Dr. Derek Tsang is an associate professor in the Department of Radiation Oncology at the University of Toronto. He is a radiation oncologist at the Princess Margaret Cancer Centre and Hospital for Sick Children in Toronto, Canada. He completed his medical training at Queen’s University, followed by a residency at the University of Toronto. He obtained fellowship training in pediatric radiation oncology at St. Jude Children’s Research Hospital in Memphis, Tennessee, and he holds a master’s degree in clinical epidemiology from the Harvard T.H. Chan School of Public Health. Dr. Tsang’s research interests include evaluating re-irradiation for recurrent tumors and reducing the late effects of radiotherapy. He participates in international cooperative group studies with the Children’s Oncology Group and NRG Oncology, and he also serves as an associate editor for the Red Journal and sits on the editorial board for Neuro-Oncology. He joined the Princess Margaret Cancer Centre in 2017, where he serves as Site Group Lead for the Paediatric Radiation Therapy Program. Additionally, he is a member of the adult central nervous system (CNS) and eye tumor site groups. His clinical practice includes pediatric oncology, adult neuro-oncology, and stereotactic radiosurgery for intracranial neoplasms.
Dr. Christina Tsien is a professor of radiation oncology and molecular sciences (PAR) in the Johns Hopkins School of Medicine and the director of the Johns Hopkins National Proton Therapy Center in Washington, D.C. Dr. Christina Tsien received her medical degree from the McGill University Faculty of Medicine, located in Montreal, Canada. She then went on to complete her residency in radiation oncology at the McGill University Health Center, as well as a fellowship at the University of Michigan. She was previously a professor in the Department of Radiation Oncology at the Washington University School of Medicine, located in St. Louis, Missouri. Dr. Tsien holds leadership roles in several professional societies, such as the Radiation Therapy Oncology Group, the Society of Neuro-Oncology, the National Cancer Center Network, the American Society of Clinical Oncology, and the American Society for Therapeutic Radiation Oncology.
